Hong Kong market could open cash flood gates for U.S. biotechs
June 14, 2018 at 10:18 AM EDT
June 14 (Reuters) - When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent.